齐鲁晚报.齐鲁壹点樊伟宏 对于一家拥有80余年历史的红色药企而言，科研不仅是发展的速度，更是生命的厚度。 当时间的指针拨向2026年2月底，山东新华制药（000756）股份有限公司(简称"新华制药")一年一度的"新春科研座谈会"如期而至。若将镜头拉长，回看自 2024年、2025年直至今日的几场座谈会，会发现这面映照企业科研生态的镜子，既映照出不变的初心，也折射出时代的流变。 这种氛围的延续，源于新华制药骨子里对技术的敬畏。从1943年胶东抗日根据地一路走来，科技兴企不是挂在墙上的标语，而是刻在基因里的信条。每年 新春伊始，将科研人员奉为"座上宾"，正是这家老牌药企在激烈的行业竞争中保持战略定力的秘诀。 质变 如果说"尊重科研"是永恒的基调，那么会议桌上的核心议题，则在短短三年间发生了深刻的变化。 将视线拉远，新华制药这三年座谈会氛围的微妙变化，与整个中国制药行业的跌宕起伏紧密相连。 在"同"与"不同"的交织中，新华制药2026年的发展路径，正逐渐清晰。 不变的"C位" 如果将2024年、2025年及2026年的参会名单并列铺开，一个显著的"同"跃然纸上。 无论是2024年2月中下旬，还是2025年2月初，抑 ...

2026 年 02 月 27 日 基础化工 PVC 困境反转，助剂行业有望同步受益 本轮景气修复 事件： PVC 困境反转，开年以来价格持续上行，根据百川盈孚，截至 2026 年 2 月 25 日，PVC 市场价格 4547 元/吨，较年初上涨 6.8%。 PVC 景气回暖有望提振助剂需求： 2026 年以来，受"反内卷"政策持续深化、差别化电价试点逐步推行 以及出口退税政策取消等多重因素共同驱动，国内 PVC 市场景气度 稳步回升，价格整体呈现震荡上行态势。根据百川盈孚，截至 2026 年 2 月 25 日，PVC 价格为 4547 元/吨，较年初上涨 6.8%。作为 PVC 加工中不可或缺的关键材料，助剂在提升产品综合性能、优化加工工 艺与拓展应用场景等方面发挥着核心作用。随着 PVC 行情回暖，产业 链整体情绪或趋于积极，下游制品企业开工意愿有望增强，预计将带 动对高性能助剂的采购需求逐步释放，助剂行业有望同步受益于本轮 景气修复。 998948033 PVC 助剂体系丰富、品类众多： PVC 助剂涉及多个品类，其中重要的稳定剂包括乙酰丙酮盐、赛克、 DBM/SBM 等；重要的加工助剂及抗冲改性剂包括 ...

津巴布韦收紧锂精矿出口，供给扰动再现 [Table_Industry] 其他小金属 碳酸锂行业事件点评 | [姓名table_Authors] | 电话 | 邮箱 | 登记编号 | | --- | --- | --- | --- | | 李鹏飞(分析师) | 010-83939783 | lipengfei2@gtht.com | S0880519080003 | | 魏雨迪(分析师) | 021-38674763 | weiyudi@gtht.com | S0880520010002 | 本报告导读： 津巴布韦禁止锂精矿出口，在短期对全球锂的供给造成较大扰动，预期锂价偏强运 行。 [Table_Report] 相关报告 其他小金属《指标再度收紧，供给刚性挺价》 2025.04.23 其他小金属《开采指标下调，钨矿供应偏紧》 2024.03.20 投资要点： 证 券 研 究 报 告 请务必阅读正文之后的免责条款部分 股 票 研 究 行 业 事 件 快 评 股票研究 /[Table_Date] 2026.02.26 [Table_Summary] 维持"增持"评级。碳酸锂行业供给偏紧，库存持续去化，津巴布 韦禁 ...

证券日报网讯 2月10日，新华制药在互动平台回答投资者提问时表示，公司始终致力于心无旁骛发展医 药主业，努力为各利益相关方创造更多回报。 （文章来源：证券日报） ...

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - Xinhua Pharmaceutical has successfully obtained the necessary regulatory approval for its Glucosamine Sulfate Capsules, indicating a significant step in expanding its product offerings in the pharmaceutical market [1]

Group 1 - The European Central Bank (ECB) President Lagarde will discuss the EU economic situation and ECB activities on February 9, with Eurozone January CPI falling to 1.7% and core CPI to 2.2%, both below the ECB's 2% medium-term target [1] - The demand for electronic storage and CPU orders is surging, with capital expenditure and orders in the computing sector maintaining high growth, indicating a sustained improvement in industry conditions [1][15] Group 2 - The Shanghai Composite Index closed at 4123.09 points, up 1.41%, while the Shenzhen Component Index rose 2.17% to 14208.44 points, and the ChiNext Index increased by 2.98% to 3332.77 points, with total trading volume reaching 2.25 trillion [2] - The retail sector is experiencing a full recovery in travel demand during the Spring Festival, with flight bookings up 10% and hotel bookings increasing by over 15% [3] Group 3 - The beverage sales during the Spring Festival are strong, with notable growth in various brands, indicating a robust demand across food and beverage categories [5] - The high-end liquor market is stable, with significant growth in premium brands, while the real estate liquor segment is expected to see a turning point mid-year [6] Group 4 - The coal supply is tightening due to reduced export quotas from Indonesia, leading to a rapid increase in coal prices, which have rebounded from a low of $38 to $49.27 [6] - The high-end consumer market is gradually recovering, with a target of double-digit growth set for 2026, particularly in luxury and soft luxury segments [7] Group 5 - The new RWA regulations in Hong Kong clarify the non-monetary nature of virtual assets and define the path for RWA, with expectations for the secondary market to open in 2026 [8][9] - The home appliance market shows significant differentiation in sales performance, with black electronics and washing machines growing, while air conditioning and refrigerators decline [10][11] Group 6 - The demand for new energy sectors is increasing, with lithium carbonate prices at 130,000, and significant growth expected in sodium battery applications and wind power orders [13] - The computing-related industry is making significant progress, with Nvidia's quartz glass substrate samples being delivered and expected improvements in production efficiency [14] Group 7 - The overseas AI capital expenditure is surging, with major companies like AWS and Google significantly increasing their capital spending, driving demand across the AI supply chain [16][17] - The optical module market is experiencing rapid growth, with demand expected to double by 2026, particularly in data centers [20]

Core Viewpoint - Xinhua Pharmaceutical has received approval from the National Medical Products Administration for the registration of glucosamine sulfate capsule, which is classified as a Class 4 chemical drug and a Class A non-prescription drug, aimed at treating primary and secondary osteoarthritis [1] Group 1 - The glucosamine sulfate capsule is available in specifications of 0.25g or 0.314g [1] - The drug has been included in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug List (2025) as a Category B product [1]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Group 1 - The approval signifies a regulatory milestone for the company, enhancing its product portfolio in the pharmaceutical market [1] - Glucosamine Sulfate Capsules are aimed at addressing a significant medical need in the treatment of osteoarthritis, a common joint disorder [1]

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Glucosamine Sulfate Capsules, which are primarily used for the treatment of primary and secondary osteoarthritis [1] Company Summary - The approval of Glucosamine Sulfate Capsules marks a significant milestone for Xinhua Pharmaceutical, enhancing its product portfolio in the orthopedic treatment sector [1] - The clinical application of this product targets a growing market for osteoarthritis treatments, indicating potential revenue growth for the company [1] Industry Summary - The approval aligns with the increasing demand for effective treatments for osteoarthritis, a condition affecting a large segment of the population [1] - The pharmaceutical industry is witnessing a trend towards the development of specialized medications for chronic conditions, which may lead to increased competition and innovation in the market [1]